With huge regulatory milestones such as the FDA approval of a gee therapy treatment for Spinal Muscular Atrophy and many more gene therapies headed towards later stage development and the continuous expansion of the gene therapy landscape, the need for repeatable and cost-effective process development is more important than ever.

The first Gene Therapy Process Development Summit will unite 60+ process development, CMC, MSAT and regulatory experts in Philadelphia. There are a limited number of partnership opportunities available, including speaking positions across our agenda. If you provide process development or vector engineering services and technologies that would benefit our niche industry audience, now is the time to secure new business and form connections with top biopharma companies seeking development solutions to progress their products to market.